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     INTRODUCTION 
  Within public health facilities in Africa, malaria is largely 
diagnosed on clinical grounds alone, and fever cases are rou-
tinely treated without laboratory confirmation.  1   Malaria 
microscopy, when available, is often of poor quality.  2,  3  However, 
with the high costs of the new-generation artemisinin combina-
tion therapy (ACT), and concerns about development of drug 
resistance caused by drug overuse, many donors and health 
system managers are searching for ways to improve the ratio-
nal use of drugs for malaria treatment. Additionally, in many 
malaria-endemic areas, intense malaria control activities and 
rapid urbanization have led to decreasing clinical malaria inci-
dence rates. As a consequence, the malaria-attributable rates 
in fever episodes have been decreasing, further increasing the 
need for improved diagnostic strategies.  4  
  The modern generation of histidine-rich protein 2 (HRP2) 
antigen-based rapid diagnostic tests (RDTs) has been shown 
in trials to have high sensitivity and specificity for the diagno-
sis of  Plasmodium falciparum  infection among clinical patients 
in Africa.  5,  6   Several studies have shown that the sensitivity of 
RDTs can be higher than expert microscopy and thus far more 
accurate than routine microscopy.  6–  9  
  There are potential drawbacks to the use of RDTs for rou-
tine malaria diagnosis, including the persistence of the tar-
get antigen in the bloodstream for up to several weeks after 
an infection has been treated. Thus, RDTs cannot be used to 
measure treatment success.  10–  12   Additionally, such tests cannot 
determine parasite load and their specificity may vary with the 
setting.  5  
  Although more accurate laboratory diagnosis may help to 
rationalize anti-malarial drug use at health facilities in Africa, 
there is also a clear possibility that any cost savings made 
from the reduction of anti-malarial prescriptions may be out-
weighed by increases in prescription of antibiotics or other 
drugs to treat patients with negative test results.  13  Additionally, 
RDTs add cost to case management, which is not inversely 
proportional to the number of patients tested, as is the case 
for microscopy, and which could outweigh cost savings from 
reduced anti-malarial consumption.  14   The effects of diagnos-
tic changes will also depend on the adherence of clinicians to 
the diagnostic result, the frequency with which they request 
a test, and the prevalence of parasitemia among the clinical 
population.  15,  16  
 There is a sizable body of literature in which the implications 
of improving malaria diagnostic methods, including empirical 
and modeling studies, have been reported. The results of the 
empirical studies have shown it may be possible to reduce aver-
age cost per patient and household costs through improved 
malaria diagnosis and that such interventions could be imple-
mented in a highly cost-effective manner.  13,  16–  18  
  Modeling studies have helped to confirm and highlight 
the myriad factors that could influence the cost-effective-
ness and overall cost-saving potential of improved diagnosis. 
The main factors that influence the desirability of one test-
ing strategy over another relate to the proportion of febrile 
cases that are parasite positive, the sensitivity and specificity 
of the new method and its alternatives, the costs of the tests, 
clinicians’ adherence to test results, and the cost of drug reg-
imens prescribed to parasite-positive and parasite-negative 
patients.  13,  14,  16–  20  
  Because the potential for cost savings appears to be highly 
situation dependant, it is necessary to evaluate the economic 
implications of the decision to shift to RDTs locally and at 
specific levels of the health care system. Although models can 
be used to explore these implications, there is still a strong 
rationale to assess alternatives and validate models empiri-
cally in representative settings.  21   This report describes a study 
of the economic implications of the implementation of diag-
nosis with RDTs in a low-endemicity urban African setting in 
Dar es Salaam, Tanzania. 
   MATERIALS AND  METHODS 
  Study  area.     Dar es Salaam is the economic capital of 
Tanzania. It is a large urban area (population approximately 
three million) with highly heterogeneous land use, including 
commercial districts, industrial districts, residential districts, 
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urban slums, and areas with high levels of urban agriculture.  22  
As a result, there is high variability in the number of  Anopheles  
spp. breeding sites and thus adult mosquito densities across the 
city. As of 2009, this city is considered a low but stable malaria 
transmission area: entomologic inoculation rate »1.3, with low 
parasite prevalence (< 10% in the general population).  23   All 
health facilities included in the costing exercise are located in 
densely populated low-income areas, although the catchment 
area of one facility (Kawe Dispensary) also includes some 
peri-urban and higher-income areas. 
  Twelve public health facilities (three hospitals and nine 
primary health care facilities) were selected for inclusion in 
a trial of RDT rollout. The three hospitals were assigned to 
receive the RDT intervention, and the nine primary care facil-
ities were randomly assigned to either receive the RDT inter-
vention (experimental) or not receive it (control).  24   Of these 
facilities, six primary health care facilities were included in the 
costing exercise. Four primary care facilities were experimen-
tal facilities in which RDTs replaced routine microscopy for 
the diagnosis of malaria. Two primary care health facilities 
remained as controls with only routine microscopy. These six 
facilities were selected because this evaluation was targeted 
at the primary care level, and these facilities were the most 
comparable in terms of patient population, size, and numbers 
of monthly consultations. Sample size was calculated using 
EpiInfo version 3.4.1 (StatCalc Module; Centers for Disease 
Control and Prevention, Atlanta, GA) with the aim of being 
able to measure a 25% difference in arithmetic mean patient 
costs between RDT and control facilities with 95% signifi-
cance and 80% power. 
      Collection of patient and facility costs and resource use.  
  Costing was conducted from the patient and provider 
perspectives. A large survey examining the effects of RDT 
introduction on health worker practices, and patient response 
was used as a platform for collecting patient-specific and facility 
costs. This survey was the second in a pre–post cross-sectional 
survey evaluation of the RDT intervention (that consisted of 
training of health workers in February 2007, initiation of RDT 
use at the end of March 2007 and supervision on site 1, 2, 5, 
10, and 15 months after RDT introduction) and conducted 
15–18 months post-intervention from July through September 
2008. Within the six selected facilities, inclusion criteria were 
1) first consultation for the present complaint (not a follow-up 
visit), 2) absence of severe disease, and 3) main complain 
not trauma related. Eligible patients or caretakers of young 
patients were included if they gave oral informed consent to 
participate. Their consultation was then passively observed 
by a survey worker with clinical training. These patients or 
caretakers were questioned during an exit interview, which 
included questions relating to their perceptions of the clinical 
and laboratory consultation, and episode-related expenditures 
and any previous treatment seeking and related expenditures. 
The questionnaire also probed travel time and costs, time 
spent accessing the facility, and missed work or lost income 
due to attendance at the facility and/or any time taken to care 
for the patient at home. 
  All patients or caretakers who participated in the exit inter-
view (and therefore had costing questions) were requested to 
return to the same health facility one week later for a follow-
up interview. They were also provided with a small incentive 
to cover transportation costs. At follow-up, all patients or care-
takers were administered a second questionnaire that solicited 
information on their current health status and any treatment-
seeking activity or expenditure during the intervening week, 
and lost income and time taken to care for the patient at home. 
They were also asked about the previous consultation and any 
associated expenditures, mainly as a check on consistency, and 
to potentially garner information about informal payments. If 
in-person follow-up was not possible, we attempted a short-
ened follow-up interview by mobile telephone. All follow-up 
patients who reported at a health facility were tested with 
an HRP2-based RDT to check for missed infections, and to 
identify persons with false-negative or false-positive results in 
the control facilities because of the persistence of the HRP2 
antigen in treated patients. Persistence of the antigen was low 
(< 33%) in previously RDT-positive and appropriately treated 
patients. Thus, such results for the second RDT were not of use 
for determining numbers of correct diagnoses. For the patients 
who were positive by RDT during follow-up, it was ascer-
tained whether they had received appropriate first-line treat-
ment and whether their condition had improved. If this was 
not the case, we ensured that they were subsequently treated 
for malaria at the health facility. 
  To assess treatment costs to the provider a health facility 
survey was conducted in the six facilities participating in the 
cost study to identify per patient resource use at the facility 
level. In-charge interviews and a health facility level data sur-
vey instrument were used to collect information on the num-
ber of outpatients and malaria cases seen at the facility during 
the past three years and on the number of blood slides and 
RDTs performed. Additionally, we collected information on 
numbers and grades of staff and estimated effort dedicated 
to outpatients. We also collected additional information used 
to calculate overhead and patient visit costs, including facil-
ity’s spending on electricity, water, other overhead costs, and 
the numbers of capital items in the facility, including micro-
scopes and other clinical equipment. Facility records were 
also used to collect information on the use of consumables 
including laboratory books, Giemsa stain, blood slides, lancets, 
syringes, and other consumables. We measured resource use 
at each of the six facilities through a questionnaire adminis-
tered to the in-charge of health facility and by collection of 
routine data on facility use, numbers of outpatients treated, 
numbers of malaria test performed, and records of consum-
ables used. Additionally, we conducted data collection at the 
central offices of the City Medical Office of Health to esti-
mate the costs of construction of health facilities and other 
costs, which we could not obtain directly from the health facili-
ties themselves, including salary ranges for various grades of 
health workers. 
   Valuation  of  resource  use.     Costs of resource inputs were 
determined for the provider costs on the basis of 1) the 
Tanzania pharmaceutical and supply price list for 2008, and 
2) interviews with the appropriate financial managers of the 
Dar es Salaam City Medical Office of Health. Information 
on drug prices was obtained from the International Drug 
Price Indicator Guide database published by Management 
Sciences for Health or from a World Health Organization–
AFRO database of indicator drug prices.  25,  26   Patient costs were 
valued according to patients reported expenditures and lost 
income. 
  Costs for the initial implementation of RDTs, includ-
ing training and quarterly supervisory visits, were calcu-
lated based on reported expenditure and activities, excluding 63 COST SAVINGS WITH RDT IN DAR ES SALAAM?
specific research costs. Costs were reported in the local cur-
rency (Tanzanian shillings [TSH]), U.S. Dollars (USD), or 
Swiss Francs. All costs were converted to USD by using offi-
cial exchange rates for the year in which the cost occurred 
and adjusted into a common year (2008) using the U.S. gross 
domestic product deflator.  27   Capital costs were discounted and 
annualized by using a 3% discount rate and assumed lifetimes 
for equipment based on expert opinion and past literature. All 
costs attributable to RDT implementation were then divided 
by the estimated total number of RDTs performed in the nine 
experimental (from the full trial) health facilities (328,000–
435,000) over the entire duration of the project (approxi-
mately two years) to calculate an average implementation cost 
per test. The number of tests was estimated in two ways: the 
first and lower number was the number of RDTs performed 
according to facility records, and the second and larger num-
ber referred to the number of RDTs delivered to the facilities 
according to project records. This range had little effect on the 
cost of implementation per test (excluding the cost of the test 
itself). 
  For provider costs, all costs were related to their allocation 
to outpatient services (as opposed to maternal and child health 
services) and then related to the number of out-patients seen 
at the facility during the period when their consumption could 
be measured (2005–2008). Because some resource use could 
not be measured at each facility because of missing records 
(26% of requested records were missing), these costs have 
been estimated by using the mean values per patient from the 
facilities in which information could be collected. Prices of 
drugs have been adjusted to account for transport costs and 
wastage according to the following assumptions. Drugs costs 
were inflated 20% over actual costs to adjust for wastage, then 
an additional 10% for local transport, and finally an addi-
tional 10% for international transport when cost, insurance, 
and freight prices were not available. 
   Statistical  analysis.     We tested the differences in patient 
expenditure and provider costs by using two statistical tests. 
We first applied the Kruskal-Wallis test for equality of pop-
ulations. We used this test because, as is typical of expendi-
ture data, the distribution of patient-specific provider costs 
and patient expenditures was highly non-normal due to a 
significant right skew and a large zero mass. Thus, perform-
ing significance testing with a non-parametric method was 
necessary. 
  Additionally, we used non-parametric bootstrapping to esti-
mate confidence intervals for each expenditure value. This 
approach was adopted because alternative non-parametric 
methods do not compare arithmetic mean costs, transforma-
tion of the data to a log scale would result in comparison of 
geometric means, and such transformation did not result in a 
normal expenditure distribution. Method studies and reviews 
have suggested this method to appropriately deal with the 
need to compare arithmetic means and generate confidence 
intervals for such data.  28,  29  
  Total time for patient visits to the health facility was nor-
mally distributed and thus amenable to standard parametric 
tests. Data was entered in EpiInfo 3.4.1 (Centers for Disease 
Control and Prevention) and analyzed by using STATA ver-
sion 9.2 (Stata Corp., College Station, TX). 
  The study protocol and related documents were reviewed 
and approved by the National Institute for Medical Research 
Review Board in Tanzania. 
    RESULTS 
  General  results.     A total of 333 patients were recruited dur-
ing consultation at each of the six selected facilities for exit 
interviews, and 259 patients were successfully admin  istered 
an exit interview. The final rate of follow-up (for patients 
participating in the full costing study) was 84% and is shown 
in   Figure 1  . No patients or clinicians refused the initial con-
sultation observation. At the 5% significance level, patients in 
RDT facilities were no more likely to attend the exit inter-
view than those in control facilities; after stratifying by the 
portion of the patient population more than five years of age, 
differences were less significant. Patients who were lost to 
follow-up were not significantly different from those who were 
successfully re-interviewed based on several demographic 
measures (  Tables 1     and   2  ). No significant differences were 
found for age distribution, patient sex, method of travel to 
and from the health facilities, or occupation of the patients’ 
head of household. Additionally, we found no significant 
differences for the same set of measures between facilities 
that offered RDTs and those facilities that did not offer RDTs 
(  Tables 1   and   2  ). Unfortunately, patients who were more than 
five years of age were significantly more likely (29% versus 
15%) to leave the health facility before completing the exit 
interview. 
            Of  the  259  patients  who  were  administered  exit  interviews, 
178 were interviewed at experimental facilities (with RDTs) 
and 81 were patients at control facilities (no RDTs). Within 
the RDT facilities, patients were significantly less likely than 
in control facilities to receive results for a laboratory test for 
malaria (84% versus 95%;   P   = 0.009, by Fischer’s exact test), 
a difference that was also significant in patients ≥ 5 years of 
age (86% in RDT facilities versus 98% in control facilities; 
  P   = 0.04) but not in children less than five years of age (82% 
in RDT facilities versus 92% in control facilities;   P   = 0.13). 
Patients in RDT facilities were also significantly less likely to 
have a positive test result for malaria parasites (14% versus 
43%;   P   < 0.001). Although in control and RDT facilities large 
fractions of all patients received laboratory diagnosis, clini-
cians in the RDT facilities appeared to be more parsimonious 
in their use of tests, at least among adults. 
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  Adults were significantly more likely than children less than 
five years of age to have positive results for malaria in control 
facilities, but not in RDT facilities (55% versus 28% in con-
trol facilities;   P   = 0.016 and 15% versus 13% in RDT facilities;   
P  = 0.69). These results clearly confirm the problem with micro-
scopic examination, and the low quality of routine micros-
copy was confirmed in more detailed studies in the same 
facilities.  3  
  Patients within RDT facilities were significantly less likely 
to receive the first-line anti-malarial drug artemether/lumefan-
trine (ALU) (Coartem™; Novartis, Basel, Switzerland) (ALU) 
compared with patients in control facilities. This finding was 
seen when the analysis was restricted to patients who left the 
facility with any drug prescription and all patients observed: 
12% versus 52%;   P   < 0.001 (with any prescription) and 10% 
versus 48%;   P   < 0.001 (all patients). This difference remained 
highly significant regardless of the age of the patient. 
  Patients in RDT facilities were also more likely to receive 
ALU in correct correspondence with the results of their diag-
nosis. When only patients with a laboratory diagnosis were 
examined, those in RDT clinics received ALU in correspon-
dence with the laboratory diagnosis 95% of the time ver-
sus 82% in control facilities (  P   = 0.002). Because a related 
study has shown that most positive blood slide results in con-
trol facilities are false-positive results (Kahama J and others, 
unpublished data), it follows that high clinician compliance 
with microscopy results leads to overuse of anti-malarial drugs. 
Patients less than 5 years of age appeared no more likely to be 
correctly prescribed ALU than patients ≥ 5 five years of age 
(93% for patients < 5 years of age versus 88% for patients ≥ 
5 years of age;   P   = 0.17). Differences remained statistically 
insignificant when restricted within either RDT facilities or 
within control facilities. 
      Implementation costs of RDT program (provider).    Cost 
data on implementation was collected over a 14-month 
period. During this period, approximately 435,400 RDTs 
were issued to implementing facilities, and use data indicated 
that approximately 330,000 RDTs for malaria had been 
performed. Because of this high volume of tests, the cost of 
implementation training and support for RDT rollout was 
relatively low when considered per test. The total cost of the 
RDT intervention over this period (not including the test 
kits) was estimated to be $16,946 in 2008 USD or $1,883 USD 
per implementing facility. Thus, we estimated that the cost of 
implementation per RDT (excluding the test kits themselves) 
was between 0.04 USD and 0.05 USD. The test kits themselves 
were estimated to cost USD 0.66 each. When calculating the 
cost per patient in RDT clinics, we include the cost of RDT 
implementation. 
  The bulk of the expenses went to staff salaries for the imple-
mentation of the RDT rollout (72%) and for training and 
quality control at the implementing facilities (22%). The only 
other substantial line item cost was transport, which accounted 
for 3% of the total cost of implementation. 
      Patient perspective: Direct costs (expenditure).    Patient 
costs consist of two main parts: direct costs due to expenditure 
on medicines, transport, diagnostics, or other health services, 
and indirect costs, such as lost productivity or the opportunity 
cost due to time spent seeking care. We attempted to measure 
direct costs and indirect costs. 
  Patient expenditures were directly reported by patients. 
  Table 3   shows arithmetic mean expenditure per patient in 
RDT or control facilities arising before and during the first 
consultation, and after the first consultation for the subset of 
patients with follow-up. Expenditures have been subdivided 
into several categories, and are reported in TSH and USD. 
       Table  3   shows  that  significant  differences  in  reported  expen-
diture were found between patients at RDT clinics and those 
at control clinics. Patients’ mean total expenditures were lower 
in RDT clinics (USD 1.02) compared with control clinics 
(USD 1.33), and were significantly different by the Kruskal-
Wallis test for equality of populations. Patients’ mean expen-
diture on drugs was 0.36 USD lower in RDT clinics than in 
control clinics. 
    Table 4   shows bootstrapped means and bias corrected con-
fidence intervals for each of the parameters shown in   Table 3  . 
Each estimate is based on 10,000 re-samples of the observed 
data. 
 T able  2 
    Comparability of control and experimental populations, and those lost 
to  follow-up, Tanzania *   
Patient method of 
travel to health facility
Lost to follow-up, 
n = 42
Not lost to 
follow-up, n = 214
RDT facility, 
n = 175
Control 
facility, n = 81
Walking 61.7 60.8 61.7 61.7
Mini-bus 33.3 35.5 34.9 35.8
Other 0.0 3.7 3.4 2.5
  P  †  0.529 1.000
  *  RDT  =  rapid  diagnostic  test.  
  †  By  Fischer’s  exact  test.  
 T able  1 
    Comparability of control and experimental populations, and those lost 
to  follow-up, Tanzania *   
Characteristic No. Estimate
95% Confidence 
interval   P  †  
Proportion of patients > 5 years of age
Control facility 81 51.9 41.0–62.7 0.49
RDT facility 178 47.2 39.9–54.5
Lost to follow-up 42 59.5 44.7–74.4 0.12
Not lost to follow-up 217 46.5 39.9–53.2
Proportion of patients who were female
Control facility 81 55.6 44.7–66.4 0.87
RDT facility 178 54.5 47.2–61.8
Lost to follow-up 42 54.8 39.7–69.8 0.99
Not lost to follow-up 217 54.8 48.2−61.5
  *  RDT  =  rapid  diagnostic  test.  
    †    By Pearson’s chi-square test (degrees of freedom = 1).   
 T able  3 
  Patient  expenditures, Tanzania *   
Type of 
expenditure Facility No.
Mean cost per patient
Standard 
deviation (TSH)   P  †   TSH U.S. $
Care pre-HF RDT 178 89 0.07 630 0.506
Control 81 46 0.04 298
Drugs at HF RDT 178 464 0.38 1,060 0.002
Control 81 902 0.74 1,407
Out-patient 
charges
RDT 125 79 0.06 117 0.347
Control 56 104 0.08 129
Laboratory 
fee at HF
RDT 122 245 0.20 411 0.841
Control 56 252 0.21 431
Post visit RDT 126 198 0.16 1,008 0.956
Control 56 70 0.06 447
Travel RDT 178 362 0.30 897 0.779
Control 81 270 0.22 440
Total RDT 122 1247 1.02 2,021 0.033
Control 56 1630 1.33 1,826
    *    TSH = Tanzanian shilling; HF = health facility; RDT = rapid diagnostic test. Totals are 
different than sum of means because of varying sample sizes for each group   
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      Arithmetic  mean  patient  expenditures,  when  reduced  into 
smaller component parts, failed to show significant differences 
in all but the line item expenditure for drugs at the first health 
facility visit, which was highly significantly different in RDT 
clinics (TSH = 464 [USD = 0.38] versus TSH = 902 [USD = 
0.74];   P   = 0.002, by Kruskal-Wallis test). However, boot-
strapped confidence intervals showed that the difference was 
only close to statistical significance. 
  The similarity of expenditure across the two types of facili-
ties helped to support our assumption that the populations of 
patients in control and RDT facilities were similar because the 
cost of transportation and actions taken before attending the 
health facility would not be expected to be significantly dif-
ferent between the two groups. Furthermore, it supports the 
argument that effects on patient expenditures were largely 
limited to those on drug purchases. Expenditures on drugs at 
the health facility accounted for the largest single component 
of patient expenditure, followed by laboratory fees and travel 
costs. 
    Patient  perspective:  Indirect  costs.     Additionally,  patients 
incurred indirect costs through lost income, reduced pro-
ductivity, and the opportunity cost of lost time caused by 
attending the facility either as patients or as caretakers of 
patients. One hundred eight (42%) patients or caretakers 
reported missing work to attend the health facility. Of that 
group, 85% reported lost income as a result. Neither result 
was significantly different at the 10% level between RDT 
and control facilities (  P   = 0.16, degrees of freedom = 1 and 
  P   = 0.66, degrees of freedom = 1). Among those reporting 
lost income, mean lost income was reported as 7,175 TSH 
(5.87 USD), a figure that was not significantly different 
between control and RDT groups (  P   = 0.16, by Kriskal-
Wallis test). This figure is significantly larger than patients’ 
expenditures on all other categories. For patients who lose 
income to attend the facility, the opportunity cost of facility 
attendance is far larger than the direct costs of health care 
and such large opportunity costs might prevent significant 
numbers of persons from accessing care. 
  Total time per visit, including transportation time, was mea-
sured by adding estimates of time at which patients or care-
takers left their home or work place to attend the facility to 
the time they spent at the health facility (determined by the 
time of the start of their exit interview), with an additional 
time factor added for their estimated time to return home. 
In control clinics, mean time per visit was estimated to be 
4.7 hours, and in RDT clinics, it was estimated to be only 
4.0 hours (  t   = 2.8703,   P   = 0.005). Thus, being a patient in an 
RDT clinic in our sample was associated with approximately 
42 minutes shorter total visit time. Although a certain amount 
of this variation can be attributed to slightly shorter travel times 
to RDT facilities (mean travel time = 35 minutes) compared 
with control facilities (44 minutes;   P   = 0.058), we observed a 
mean difference of approximately 9 minutes of travel in each 
direction, or a total of 18 minutes. Reduced waiting times and 
total visit times might help to reduce the opportunity costs 
of facility attendance and thus could improve access to care, 
although reductions seen are small (< 10%) in relation to total 
visit time. 
   Provider  perspective.     In this analysis, we focus on gross 
provider economic costs and not net costs, which would 
account for the collection of user fees by health facilities. 
  Table 5   lists the costs that were included in the analysis. 
            Table 6   shows the results of the provider perspective anal-
ysis for the RDT and control facilities. The table shows the 
results of non-parametric tests for each of three sub-divisions 
of total provider costs. These costs are analyzed either within 
control or experimental facilities. Drug costs represent the 
cost to the provider of all drugs and prescription provided 
to a given patient. Facility cost is the cost of the commodities 
whose use is measured at the facility level but not linked to 
specific patients (overhead, staff costs, equipment, and general 
consumables, excluding drug costs). Thus, there are only six 
observations corresponding to the number of facilities in our 
 T able  4 
    Results of non-parametric bootstrap for confidence interval estima-
tion of patient expenditures, Tanzania  *     
Type of expenditure Facility
Mean cost per 
patient
95% Bias corrected 
confidence interval
2008 U. S. dollars TSH
Expenditure for care 
pre-HF
RDT 0.07 0.02–0.18
Control 0.04 0.01–0.12
Drug expenditure 
at HF
RDT 0.38 0.27–0.53
Control 0.74 0.52–1.03
Out-patient charges RDT 0.06 0.05–0.08
Control 0.08 0.06–0.12
Laboratory fee at HF RDT 0.20 0.15–0.27
Control 0.21 0.13–0.32
Post visit expenditure RDT 0.16 0.04–0.34
Control 0.06 0.00–0.22
Travel expenditure RDT 0.30 0.21–0.43
Control 0.22 0.15–0.31
Total expenditure RDT 1.02 0.76–1.36
Control 1.33 0.99–1.77
    *    TSH = Tanzanian shilling; HF = health facility; RDT = rapid diagnostic test. Totals are 
different than sum of means because of varying sample sizes for each group   
 T able  5 
    Costs included in provider perspective analysis, Tanzania   
Recurrent costs
Clinical staff salaries
Laboratory technician salaries
Support staff salaries
Consumables
Drug costs
Diagnostics
Electricity
Water
Communication
Capital costs
Building and furnishings
Microscopes
Other equipment
  T able  6 
Provider costs per patient, Tanzania  *     
Type of cost 
per patient Facility No.
Arithmetic mean Standard deviation
  P  TSH U. S. dollars TSH
Drug cost RDT 178 1567 1.28 1799 0.014  † 
Control 81 2095 1.71 1938
Facility cost RDT 4 1926 1.58 903 0.161  ‡ 
Control 2 720 0.59 424
Total cost RDT 178 4440 3.63 2019 < 0.001  † 
Control 81 2833 2.32 1978
    *    TSH = Tanzanian shilling; RDT = rapid diagnostic test. Totals include drug costs, facility 
level costs, and other patient-specific marginal costs.   
  †  By  Kruskal-Wallis  test.  
  ‡  By   t  -test. Total includes other marginal costs to the facility.   66 YUKICH AND OTHERS
study. Total costs include drug costs, facility costs, and other 
marginal costs, including RDTs and consumables, which are 
patient specific rather than general consumables used for all 
patients. Significant differences were found for all costs except 
facility cost, although the latter result is compromised by the 
extremely small sample size. 
            When patients who attended RDT clinics were compared 
with patients who attended control clinics, drug costs were 
significantly lower for patients who attended RDT clinics 
(USD 1.28 versus USD 1.71;   P   = 0.014). However, total pro-
vider costs were higher for patients who attended RDT clinics 
(USD 3.63 versus USD 2.32;   P   < 0.001 for total cost). 
 We were again confronted with results that were highly non-
normally distributed, including in some cases a large zero mass 
and in all cases a significantly right-skewed distribution. Thus, 
we estimated confidence intervals by using non-parametric 
re-sampling (bootstrapping) with 10,000 re-samples for each 
outcome, excepting facility cost (  Table 7  ). 
      Bootstrapped  confidence  intervals  generally  confirm  the 
results of the Kruskal-Wallis tests. However, there are impor-
tant differences between the two results. The confidence inter-
vals for drug costs between RDT and control facilities show a 
large overlap when analyzed for all age groups. However, when 
the sample is stratified by those < 5 years of age and those 
≥ 5 years of age, a significant difference exists for patients 
≥ 5 years of age. This finding may be the result of a combina-
tion of high rates of ALU prescriptions in control facilities and 
the higher cost of this drug for adults in relation to other adult 
drugs. Once facility costs are included, the total cost of treating 
a patient, including all provider costs, is significantly higher in 
RDT facilities than in control facilities. 
   Summary  of  results.     The results indicate that in the 
presence of RDTs, drug cost savings are likely to accrue to 
patients, and may also accrue to the providers, especially for 
adults. However, whether these savings translate into overall 
cost savings is unclear. For patients, it is likely that there is 
some reduced overall spending when RDTs are available. 
However, the savings is small (USD 0.36) and it represents 
only a small component of the total economic costs to 
patients. 
  For providers, the drug cost savings is of a similar order 
(USD 0.43) as a result of RDT introduction. Unfortunately, 
these savings appear to be too small to offset the entire cost 
of RDT introduction and use. Thus, it appears that RDTs may 
increase the cost of treatment per patient in public facilities, 
despite reducing anti-malarial drug use and creating drug 
cost savings for the health system. Additionally, the cost sav-
ings arise largely from reduced anti-malarial use among adults 
who are most likely to be charged a user fee for drugs. Thus, 
the resulting reduction in user fee revenue caused by reduced 
patient drug expenditure will reduce the financial incentives 
for RDT implementation. 
    DISCUSSION 
 This study was conducted under routine conditions in health 
facilities and sampled patients were taken from six health 
facilities. Because there is likely to be a tendency towards sim-
ilar prescribing practices within facilities, the results should be 
adjusted for clustering within health facilities.  30   Unfortunately, 
because of the small sample size and small number of health 
facilities included in the study, we were unable to formally 
account for this in most of the statistical analysis. Nevertheless, 
we believe that these results are likely to be robust, although 
the extent to which they are generalizable depends on how 
representative these facilities are of typical facilities in 
Tanzania or more widely of other health systems in sub-
Saharan Africa. 
  These results are sensitive to the relative prices of malaria 
drugs and antibiotics (ALU: USD 0.41 to USD 1.60 depending 
on dosage and antibiotics: USD 0.20 to USD 3.50 depending 
on drug, dosage, and formulation) and any other drugs used 
to treat patients with positive and negative test results. It is 
possible that given changes in drug prices, our results could 
change. One of the most expensive drugs commonly used 
among these patients is ACT for malaria. Much of the drug 
cost savings seen in this study to patients and providers is 
caused by reduced anti-malarial use in RDT facilities. Thus, 
a reduction in the price of anti-malarial drugs may eliminate 
the drug cost savings we observed. Currently, a global subsidy 
scheme for antimalarial drugs is at an advanced stage and a 
virtually free drug at the country level might be a disincen-
tive to testing for malaria.  31   Subsidized provision of malaria 
RDTs should be considered in parallel to help overcome 
this problem. 
  Additionally, we chose to focus on gross provider costs. This 
focus could affect our results because it excludes health facil-
ity receipts for user fees. However, based on the evidence from 
the perspective of patients, the primary effect of RDTs was 
likely to have been a reduction in user fees caused by reduced 
prescriptions of drugs and no changes in laboratory or general 
fees. Thus, shifting the perspective to net costs at the facility 
level would have likely made RDTs appear even more costly 
than microscopy because they reduce the primary source of 
health facility user fee revenue. 
  It has been postulated in several studies that RDTs could 
produce cost savings to health facilities in low transmission 
settings.  18,  19   We show based on empirical data from six health 
facilities in Dar Es Salaam that significant drug cost savings 
and reductions in anti-malarial drug use appear to be achiev-
able in such settings. In addition, there was a large reduction 
in false-positive malaria test results because of good specific-
ity of routine RDTs. Clinicians’ compliance with test results 
was also significantly better when RDTs were in use, and this 
is likely to have contributed to the drug cost savings seen we 
 T able  7 
    Results of non-parametric bootstrap for confidence interval estimation of provider economic costs, Tanzania  *     
Type of cost 
(per patient) Facility
All ages < 5 Years of age ≥ 5 Years of age
Mean cost 95% Bias corrected CI Mean cost 95% Bias corrected CI Mean cost 95% Bias corrected CI
Drug cost RDT 1.28 1.07–1.50 1.19 0.90–1.53 1.38 1.10–1.68
Control 1.71 1.40–2.08 1.08 0.74–1.57 2.29 1.82–2.79
Total cost RDT 3.63 3.40–3.89 3.59 3.11–3.95 3.69 3.36–4.03
Control 2.32 1.99–2.69 1.72 1.37–2.22 2.87 2.39–3.38
    *    CI = confidence interval. Cost values in are 2008 U.S. dollars.   67 COST SAVINGS WITH RDT IN DAR ES SALAAM?
observed.  16   Increased compliance by providers may be a result 
of high-quality training or their perception of the increased 
accuracy of RDTs compared with their routine laboratory 
diagnostic methods. 
 However, despite demonstrable drug cost savings, we did not 
see overall cost savings caused by use of RDTs. Provider costs 
appeared to significantly increase in the presence of RDTs. 
Although some of this increase is likely caused by higher fixed 
costs within the set of facilities selected for this study, the drug 
cost savings that we observed (USD 0.43) were not likely to 
be large enough to offset the cost of the RDTs when a high 
percentage (84%) of the patients at the facility have the test 
administered. Furthermore, reduced patient expenditure on 
drugs leads to decreasing revenue from user fees, which might 
make the intervention appear economically less attractive at 
the facility level. Other considerations such as reduced effort 
at the laboratory level may partially compensate this loss. 
  Our results show that for a significant proportion of all per-
sons seeking treatment, the indirect costs of lost productivity 
far outweigh the direct costs of transportation and treatment. 
When averaged over all the patients observed, lost income 
accounted for approximately two-thirds of all costs. Other 
studies have had mixed conclusions about the balance of 
direct and indirect costs of uncomplicated malaria morbidity. 
However, there is a general consensus that indirect costs of 
morbidity form an important part of the economic burden of 
malaria.  32   Our results are consistent with a number of stud-
ies from Africa and other locations, which showed that indi-
rect costs of malaria can outweigh direct costs of treatment for 
uncomplicated episodes.  33–  36  
  Unfortunately, in the context of this study, it was not pos-
sible to measure differences in health outcomes between the 
groups of patients, or to assess whether patients were truly 
malaria infected by using expert microscopy. Thus, it was not 
possible to assess the cost-effectiveness of the intervention, 
either per health outcome or per additional correct diagnosis. 
An in-depth analysis of case management practices will deter-
mine if RDTs improved compliance with standard treatment 
guidelines and improved case management (d’Acremont V 
and others, unpublished data). That information could also be 
used to calculate a cost per additional correct treatment, as has 
been done in previous diagnostic costing studies.  14  
  An additional benefit is that with a more reliable laboratory 
test, it becomes more realistic to monitor malaria trends on 
the basis of routine data. Although it is unclear what monetary 
value such a benefit would have for the health system, substan-
tially improved knowledge of malaria incidence rates could 
lead to efficiencies in other health care domains. Distribution 
of malaria prevention and treatment resources could poten-
tially be more efficiently allocated to high-incidence areas. 
Alternatively, more accurate measures of malaria incidence 
could enhance responsiveness of health systems to malaria 
epidemics.  37   Finally, reduction of unnecessary anti-malarial 
over-use is important to limit the development of resistance 
to ACTs.  38  
  Our results show significant savings on drug expenditure 
to patients and on drug costs to providers in the presence of 
RDTs. However, the savings are outweighed by other fees and 
charges and lost income for patients, or the cost for RDTs and 
higher facility costs for providers. 
  Clinicians’ compliance with test results was higher when 
RDTs were used, which showed that they trusted this new 
technology. It is also likely that use of such tests accrues sig-
nificant other benefits, including improved case management, 
more rational anti-malarial drug use, and reductions in devel-
opment of resistance to ACTs. Although valuation of such 
benefits is outside of the scope of this work, they are highly 
important from a public health perspective. Although RDTs 
are likely to bring significant benefits to the health system in 
areas such as Dar es Salaam, these benefits may not be fully 
paid for through drug cost savings, but require additional 
investment. 
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